Related by context. All words. (Click for frequent words.) 74 metastatic GIST 72 EGFR expressing mCRC 71 novel VDA molecule 70 Telik logo TELINTRA 69 ACTEMRA TM 69 plus dacarbazine 69 Secondary endpoints include 68 MAGE A3 ASCI 68 recurrent metastatic ovarian cancer 68 Aflibercept 68 AAG geldanamycin analog 68 TO AVOID PREGNANCY WHILE 68 monoclonal antibody IgG1 Mab 68 kidney urologic 68 Achieves Primary Endpoint 68 evaluating picoplatin 67 evaluating tivozanib 67 evaluating T DM1 67 virus HCV protease inhibitor 67 investigational immunotherapy 67 mertansine 67 intravesical infusion therapy 67 Phase 2b Clinical Trial 67 prostate cancer antigen prostatic 67 metastatic pancreatic 67 Tarceva TM 67 Crofelemer budesonide foam 67 CYP#A# CYP#D# 67 Primary endpoints 67 dasatinib Sprycel ® 67 galiximab 67 candidates Azedra TM 67 Mg Usa 67 XL# anticancer compounds 66 catheter occlusion 66 EGFr expressing metastatic colorectal 66 anthracycline taxane 66 prednisone prednisolone plus 66 estramustine 66 Maximum Tolerated Dose MTD 66 carcinoma mCRC 66 5 FU leucovorin 66 interferon gamma 1b 66 By JENNIFER LEARN 66 evaluating Actimmune 66 refractory chronic lymphocytic 66 plus dexamethasone 66 Solid Tumors criteria 66 SPRYCEL ® 66 Xeloda ® 66 Combination REOLYSIN R 66 brand ciclesonide HFA 66 IgG1 monoclonal antibody 66 metastatic colorectal 66 pan histone deacetylase 66 oral prodrug 66 AN# topical anti 66 Known hypersensitivity 66 Immunotherapeutic 66 oral picoplatin 66 cisplatin gemcitabine 66 Secondary endpoints included 65 CYT# potent vascular disrupting 65 evaluating satraplatin 65 irinotecan containing 65 ® bortezomib 65 INTEGRILIN ® 65 Initiates Enrollment 65 Bayer HealthCare Onyx Pharmaceuticals 65 R lenalidomide 65 pegylated interferon peg IFN 65 novel orally inhaled 65 relapsed MM 65 myelodysplastic myeloproliferative diseases 65 R Saizen R 65 assessing T DM1 65 Platinol ® cisplatin 65 Genasense ® oblimersen 65 FUSILEV enhances 65 accumulate preferentially 65 erlotinib Tarceva ® 65 GVAX ® 65 systemic anaplastic large 65 PDX pralatrexate 65 metastatic ocular 65 MEK Inhibitor 65 Mg Uk 65 Kit CD# positive 65 STRIDE PD 65 PANVAC VF 65 5 fluorouracil leucovorin 65 vaginal candidiasis 65 Randomized Phase II 65 FEMALES SHOULD BE ADVISED 65 myocardial infarction ventricular fibrillation 65 VEGFR2 inhibitor 65 FOLFOX6 chemotherapy regimen 65 Phase #b/#a clinical 65 humanized interleukin 6 65 plus prednisone prednisolone 65 advanced metastatic renal 65 dasatinib Sprycel 65 hyperphenylalaninemia HPA due 65 novel tubulin binding 65 vinorelbine tartrate 65 Submits Biologics License Application 65 Navelbine R 65 pralatrexate injection folate analogue 65 INSPIRE Trial Phase III 65 recurrent glioblastoma multiforme 65 oncolytic virus therapies 65 Completes Patient Enrollment 65 docetaxel Taxotere ® 65 Adjuvant Treatment 65 RECIST Response Evaluation Criteria 65 Hsp# Inhibitor 65 Plaque Psoriasis 65 undergoing elective percutaneous 64 novel histone deacetylase 64 R sorafenib tablets 64 R vitespen 64 Pruvel TM 64 Prolongs Survival 64 Initiates Phase II 64 sarcoma melanoma 64 orally administered inhibitor 64 progressive metastatic prostate 64 essential thrombocythemia ET 64 castration resistant hormone refractory 64 Unigene nasal calcitonin 64 non constipating irritable 64 microbiologically evaluable 64 Demonstrates Positive 64 #rd Annual CTRC 64 lenalidomide Revlimid R 64 ALN HPN 64 induced macular edema 64 treatment naive genotype 64 substantially excreted 64 Pivotal Phase III 64 GVAX R 64 CTAP# Capsules 64 ® lenalidomide 64 HCV RESPOND 2 64 REVIVE Diabetes 64 Oral Calcitonin 64 INTEGRILIN R eptifibatide Injection 64 malignant mesothelioma Alfacell 64 modified glutathione analog 64 MOVIPREP R 64 hoFH 64 CIMZIA ™ 64 read Palintologist 64 CINQUIL 64 number NCT# ClinicalTrials.gov 64 FOLOTYN ® 64 CDK cyclin dependent 64 PROCTOCORT ® Suppository Hydrocortisone 64 Aeolus Pharmaceuticals Announces 64 3 registrational trial 64 Panzem R 64 Meets Primary Endpoint 64 antibody MAb 64 inflammatory PDE 64 mTOR kinase 64 Curaxin CBLC# 64 clinical trials Archexin 64 certain protein tyrosine 64 evaluating mipomersen 64 Hormone Refractory Prostate Cancer 64 hypereosinophilic syndrome 64 PI3K/Akt pathway inhibitor 64 papillary renal cell carcinoma 64 Vidaza ® 64 Panzem R NCD 64 sunitinib Sutent 64 Phase 1b clinical trials 64 Staphylococcus aureus Immune Globulin 64 Ovitrelle R Serostim 64 novel antimitotic agent 64 Anturol TM 64 antiangiogenesis therapies 64 ® decitabine 64 plus COPEGUS 64 achieved CCyR 64 ovarian esophageal 64 Hedgehog Pathway Inhibitor 64 receiving INTRON 64 mTOR mammalian target 64 TM pralatrexate injection 64 Empatic ™ 64 humanized therapeutic 63 RANK Ligand inhibitor 63 lexidronam injection 63 YOUR LOCAL ANIMAL SHELTER 63 FBPase 63 biologic antibody 63 lintuzumab SGN 63 sorafenib tablets 63 investigational humanized monoclonal antibody 63 ribonucleotide reductase clinically validated 63 HCD# [002] 63 Dementia Related Psychosis 63 Virulizin ® 63 relapsed refractory multiple myeloma 63 Oral Fingolimod 63 Pivotal Phase 63 CYP#A# substrate 63 Antitumor 63 cytidine nucleoside analog 63 ATRA IV 63 approved incretin mimetic 63 ADVANCE ILLUMINATE 63 Evoltra ® 63 d l leucovorin 63 recombinant PSMA vaccine 63 biomarkers predictive 63 LibiGel NDA 63 IMiDs ® 63 recurrent metastatic 63 Complicated Skin 63 successfully commercialize Iluvien 63 forodesine 63 SinuNase TM 63 Tumor Response 63 IL# PE#QQR 63 Trial Evaluating 63 Budesonide foam crofelemer 63 Suppository Hydrocortisone Acetate Rectal 63 SAR# [004] 63 CD4 monoclonal antibody 63 Cytogen marketed 63 metastatic malignant 63 Dose Limiting Toxicity DLT 63 Second Pivotal Phase 63 NASH Huntington 63 Darinaparsin 63 pain palliation 63 IMiDs ® compound 63 PNP inhibitor 63 Refractory Hodgkin Lymphoma 63 Westerplatte glory 63 R sipuleucel T 63 endometriosis ovarian cysts 63 trastuzumab DM1 T DM1 63 highly purified pasteurized 63 dose escalation clinical 63 Perforomist TM formoterol fumarate 63 systemic immunosuppressive drugs 63 pancreatic prostate 63 demonstrated antitumor activity 63 Zenvia ™ 63 PROGENSA R 63 Pruvel ™ prulifloxacin 63 Golimumab 63 Vitrasert R 63 acid phosphatase PAP 63 dependent kinase inhibitor 63 Initiates Clinical Trial 63 severe oral mucositis 63 G#DT 63 Randomized Double blind 63 targeting miR 63 TLK# 63 Phase IIb Trial 63 PEGylated Fab fragment 63 Initiated Phase 63 achieve sustained virologic 63 whose tumors overexpress 63 receptor tyrosine kinase inhibitor 63 reduce serum phosphate 63 oral ridaforolimus 63 Synta Announces 63 PROVENGE ® 63 relapsed MCL 63 Folfox 63 LymphoStat B belimumab 63 DG# compounds targeting 63 Auxilium anticipates 63 RAS MAPK pathway 63 Initiate Phase 63 refractory NSCLC 63 DIFICID ™ 63 Pralatrexate 63 hygienic cleansing 63 trastuzumab DM1 63 ZOLINZA 63 brivanib 63 vaccines oncolytic virus 63 lumiliximab 63 infliximab monotherapy 63 Peginterferon alfa 2b 63 Phase Ib II 63 included exfoliative dermatitis 63 generation DACH Platinum 63 oral nucleoside analogue 63 colorectal bladder 63 oral rivaroxaban 63 Omacetaxine 63 novel emulsion formulation 63 Immunomedics Announces 63 EGFR HER2 63 Advanced Melanoma 63 acyclovir Lauriad R 63 CRMD# 63 maximally tolerated dose 63 Oral Mucositis 63 Receives Fast Track 63 alvespimycin 63 mild hepatic impairment 63 docetaxel Taxotere R 63 FOLFOX6 63 Initiates Phase III 63 registrational Phase 63 agonistic human 63 develop HBV reactivation 63 Traci Arbios 63 hyaluronidase enzyme 62 naïve HCV 62 recurrent malignant glioma 62 CINTREDEKIN BESUDOTOX 62 AVASTIN 62 Degarelix 62 EXPLORE Xa 62 deCODE AF TM 62 * olmesartan medoxomil 62 8mg/kg 62 Elotuzumab 62 serum phosphorous 62 Emily Blunt shimmered 62 Cutaneous T 62 Entereg R 62 worsening thrombocytopenia 62 tumor lysis syndrome 62 next generation URAT1 62 trastuzumab Herceptin R 62 adecatumumab MT# 62 CYP#A# isoenzyme 62 vapreotide acetate 62 2 methoxyestradiol 62 Fludara ® 62 metastatic HRPC 62 Granted Orphan Drug 62 NeuroSTAT ® 62 stage IIIb IV 62 JAK2 Inhibitor 62 Severe Sepsis 62 ALTROPANE R 62 sapacitabine CYC# 62 TransVax ™ 62 PROSTASCINT R 62 telomerase therapeutic 62 coronary stent merged 62 includes TOLAMBA TM 62 CFTR corrector 62 Oracea TM 62 receiving chemoradiation therapy 62 alpha folate receptor 62 hypoxia selective 62 torsemide ER 62 NCCN Updates 62 Stage IIB 62 liposomal formulation 62 granted Ortec 62 SPL# Gel vaginal microbicide 62 tubulin inhibitor 62 Bronchopulmonary Dysplasia 62 vidofludimus 62 haematologic 62 CIMZIA TM certolizumab pegol 62 serum uric acid sUA 62 IMPDH inhibitor 62 Quirky chanteuses Florence 62 phase Ib 62 aflibercept VEGF Trap 62 small molecule Hedgehog 62 mocetinostat MGCD# 62 Phase IIIb clinical 62 velafermin 62 treat musculoskeletal metabolic 62 Enzastaurin 62 NicVAX TM 62 OMNARIS HFA 62 Perifosine KRX 62 neratinib 62 thalidomide Thalomid 62 First Patient Enrolled 62 ADVERSE EVENTS 62 panitumumab Vectibix 62 COPEGUS R 62 Xanafide 62 Factor Receptor 62 Medullary Thyroid Cancer 62 Submits NDA 62 cutaneous T 62 pancreas esophagus 62 fallopian tube cancers 62 XP# XP# 62 Brentuximab Vedotin SGN 62 Chemophase 62 EDEMA3 trial 62 investigational therapies 62 novel therapeutic antibodies 62 pentadentate logo R 62 liver resection surgeries 62 CCR5 inhibitors entry 62 Allovectin 7 ® 62 Demonstrates Sustained 62 ARRY # 62 Presents Positive 62 bazedoxifene conjugated estrogens 62 cetuximab Erbitux R 62 R Bortezomib 62 alfa 2a 62 including HGF ErbB3 62 Investigational Oral 62 ERBITUX cetuximab 62 ongoing Phase 1b 62 Begins Dosing 62 lymphoid malignancies 62 Janis Joplin soundalike respiratory 62 HGS ETR2 62 IONSYS TM 62 ® natalizumab 62 alefacept 62 sunitinib Sutent ® 62 sorafenib Nexavar 62 zoledronic acid Reclast 62 MKC# MT 62 Cardium Therapeutics TM 62 hypoxia activated prodrug 62 Xcytrin R 62 Shows Statistically Significant 62 GTC recombinant form 62 BENLYSTA ® 62 candidate deforolimus 62 Secondary efficacy endpoints 62 nilotinib Tasigna ® 62 Study Evaluating 62 folate analogue metabolic 62 Exelixis compounds 62 riociguat 62 plus prednisone 62 Vascular Disrupting Agent 62 pan BCR ABL 62 headache nasopharyngitis 62 either acutely decompensated 62 Hill Rom enhancing 62 phase IIb study 62 triggers apoptosis programmed 62 bevacizumab Avastin R 62 herpetic keratitis 62 xanthine oxidase inhibitor 62 XL# XL# XL# XL# 62 CIMZIA TM 62 R# #mg BID 62 #I TM# 61 Receives Orphan Drug Designation 61 REMINYL ® 61 huC# DM4 61 dihydrochloride Tablets 61 Pharmacokinetics PK 61 TRIOLEX HE# APOPTONE HE# 61 noninvasive outpatient 61 Xelox 61 pharmacodynamic PD 61 patients coinfected 61 Rigel R# 61 Zemplar Capsules 61 Intravitreal 61 nab paclitaxel 61 BCG refractory carcinoma 61 Successfully Completes Phase 61 class mGluR5 inhibitor 61 Elagolix 61 HGS ETR1 mapatumumab 61 diarrhea predominant irritable 61 MCSP respectively 61 DexaSite 61 Gorzno Poland 61 Bezielle 61 blinded randomized placebo controlled 61 Ixempra 61 following fluoropyrimidine oxaliplatin 61 prospectively defined 61 TRANSDUR ® 61 pharmacogenomic translational research 61 FDA Approves Novel 61 proprietary polysaccharide 61 P#X# antagonist 61 selective modulator 61 label Lipofen R 61 Receives Approvable Letter 61 irinotecan cisplatin 61 Shows Promise Against 61 STRATEGY FOR AN OPEN 61 metastatic colorectal carcinoma 61 cerebral somatic oximeter 61 cladribine Cladribine Tablets 61 pelvic malignancies 61 specific lectin receptors 61 Testosterone MDTS ® 61 lucinactant 61 MetroGel 61 histamine dihydrochloride 61 NEBIDO VANTAS SUPPRELIN LA 61 paclitaxel Taxol ® 61 Caroline Gabsewics 61 CCR9 antagonist 61 CG# oncolytic virus 61 Patient Enrollment 61 Relapsed Refractory 61 rapamycin kinase 61 protein tyrosine phosphatase 1B 61 indolent follicular non 61 TELINTRA R 61 bevacizumab Avastin ® 61 adalimumab Humira 61 metastatic androgen independent 61 alkylating agent 61 Solid Tumors 61 Triapine R 61 Telik Announces 61 include ColorectAlert TM 61 BLA filing 61 topically applied SEPA 61 Aztreonam lysine 61 See WARNINGS 61 toenail onychomycosis 61 basal cell carcinoma squamous 61 prospectively stratified 61 Temsirolimus 61 Prodarsan R 61 mastercard viagra pillsgeneric viagra 61 paclitaxel poliglumex 61 Malignant Glioma 61 oral proteasome inhibitor 61 viral kinetics 61 autologous cellular immunotherapy 61 concomitant cardiac 61 acetonide FA 61 telomerase inhibitor drug 61 Romiplostim 61 cyclophosphamide chemotherapy 61 heparanase 61 Onyx Pharmaceuticals Announces 61 PF # [002] 61 events thrombocytopenia neutropenia 61 Ep CAM 61 tiuxetan 61 FOR FURTHER INFORMATION ABOUT 61 plus gemcitabine 61 GTC recombinant human 61 tumor angiogenesis inhibitors 61 BEXXAR Therapeutic Regimen 61 HER2 positive metastatic breast 61 Trastuzumab DM1 61 Solazed TM 61 Phase IIb Clinical Trial 61 please visit www.advaxis.com 61 Planetwide Media My 61 pegylated interferon alpha 61 severe hypercholesterolemia 61 serious cardiovascular thrombotic 61 non nucleoside HCV 61 ACAPODENE TM 61 technology Parthenogenesis 61 ELACYT 61 FACTIVE ® 61 EGFr expressing mCRC 61 ribavirin RBV 61 fosbretabulin 61 Endologix Powerlink System 61 Tyrosine Kinase Inhibitor 61 Exherin 61 fusion enhancers 61 investigational pharmacologically unique 61 refractory metastatic 61 interferon alpha IFN 61 Associated Press Writers Jorde 61 HLA DR2 61 inflammatory autoimmune diseases 61 EGFr humanized monoclonal antibody 61 Gemzar ® 61 TAXUS Element Paclitaxel Eluting 61 Ocrelizumab 61 peptidic compound 61 cell carcinoma RCC 61 Patients Treated With 61 sUA 61 oxaliplatin Eloxatin 61 biliary tract cancer 61 Val HeFT 61 Pharmacokinetic parameters 61 CRp 61 particularly SANCTURA XR 61 Pegasys ® 61 EGFR expressing metastatic colorectal 61 MoxDuo IR 61 orally inhaled migraine 61 Response Evaluation Criteria 61 Relapsed Multiple Myeloma 61 NeoLipid R 61 Cimzia TM 61 Phase Ib clinical trials 61 miconazole Lauriad ® 61 Initiate Phase III 61 MEND CABG II 61 LHRH antagonists 61 CEA CD# Her2 61 Antitumor Activity 61 Pazopanib 61 LEP ETU 61 telaprevir dosed 61 candidate XP# 61 AND TO REOFFER 61 Romidepsin 61 methylnaltrexone bromide 61 Amgen Neulasta R 61 chronically immunosuppressed solid 61 HCV NS5B polymerase 61 oral Janus kinase 61 Proellex TM 61 pigmentary disorders 61 Study Shows Promise 61 confirmatory clinical 61 See CLINICAL PHARMACOLOGY 61 NDA Submission 61 Triapine 61 Amigal TM 61 Mylan Receives Approval 61 Phase III Clinical Trial 61 MGd 61 cortisol synthesis 61 Submits Response 61 anthracycline containing 61 delay bone metastases 61 Phase Ib Clinical Trial 61 pertuzumab 61 LungAlert TM 61 achieved ACR# 61 PEGINTRON REBETOL combination 61 CLARITY study 61 modulate ion channel 61 KRN# 61 dextromethorphan quinidine 61 BRIM2 61 Initiates Clinical 61 Quinamed 61 oral deforolimus 61 TOCOSOL Camptothecin 61 opioid induced bowel dysfunction 61 beta islets 61 Commences Phase 61 Coadministration 61 ISTA Pharmaceuticals Announces 61 Bucindolol Based 61 Phase 2b Trial 61 APPRAISE 61 PEGINTRON TM 61 gastrointestinal stromal 61 potent antiproliferative 61 bevirimat Study 61 Sustained virologic response 61 targeted radiotherapeutic 61 MGN# 61 NS5B polymerase 61 refractory cutaneous T 61 Randomized Phase 61 ALN PCS 61 oral JAK1 61 EDARBI 61 previously untreated follicular 60 Sulonex TM 60 HCV SPRINT 60 please visit http:/www.avastin.com 60 Epothilone D 60 2 inhibitor CYT# 60 Improved Progression 60 ENABLE Phase 2 60 PSMA ADC 60 By Thomas Gryta 60 Reports Preclinical Data 60 IAP inhibitor 60 pyrimidine nucleoside analog 60 punter Mariani 60 Tasigna prolongs 60 interferon beta 1a infertility 60 delivers fluocinolone acetonide FA 60 VANTAS ® 60 Files IND 60 SIX RO ROG 60 gemcitabine Gemzar ® 60 Sudhir Agrawal D.Phil 60 R ferumoxytol Injection 60 ThermoDox ® clinical 60 receiving XGEVA 60 unresectable tumors 60 Primary Hypercholesterolemia 60 6 sulfatase 60 5 HT2A serotonin 60 balsalazide disodium 60 Personalized Immunotherapy 60 Cardiac Resynchronization 60 IMiDs R 60 nicardipine 60 Pegloticase 60 POTELLIGENT ® Technology 60 Phase 2b Study 60 HDAC Inhibitor 60 mRCC 60 including eniluracil ADH 60 Catheter Associated 60 eye socket ruptured 60 low toxicity bioscience 60 Salix Pharmaceuticals Announces 60 GVAX Pancreas Vaccine 60 signal detection CTSD 60 gefitinib Iressa 60 dexamethasone Decadron 60 ZACTIMA 60 DO YOU NEED TO 60 Kamada AAT 60 Secondary endpoints 60 receiving CIMZIA #mg 60 SinuNase ™ 60 oral antidiabetic medication 60 Accelerated Partial Breast Irradiation 60 sorafenib Nexavar ® 60 KIDS FINANCIAL SKILLS 60 Cloretazine R 60 corticosteroid dose 60 miRview ™ tests 60 Zemiva ™ 60 BrachySil TM 60 HER2 expression 60 Soft Tissue Sarcoma 60 Cloretazine 60 Newly Diagnosed Multiple Myeloma 60 Panzem NCD 60 DVT prophylaxis cholesterol 60 ixabepilone 60 Phase III multicenter 60 ARCALYST ® 60 platform HDL Mimetic 60 investigational oral inhibitor 60 triciribine phosphate monohydrate 60 hormone LHRH antagonist 60 aldehyde dehydrogenase ALDH2 deficiency 60 non peptidic protease 60 proprietary intravenous formulation 60 phase IIb trial 60 GATTEX TM 60 Tesmilifene 60 TNF Tumor Necrosis Factor 60 5 Fluorouracil 60 ACR# ACR# 60 5 HT2A inverse 60 XL# inhibits 60 plus Copegus R 60 Metastatic Melanoma 60 Allovectin 7 R 60 Recurrent Glioblastoma 60 Intravenous CP 60 folinic acid FA 60 Phase 2a Clinical Trial 60 Dose Escalation 60 non splenectomized 60 Generx TM 60 Fast Track Status 60 Advanced Renal Cell 60 microsurgical disciplines 60 ENRICH trial 60 Forodesine HCl 60 huN# DM1 60 ADVEXIN therapy 60 acute peptic ulcer 60 anti VEGF aptamer 60 YONDELIS 60 compound INCB# 60 Vaxfectin ® 60 abnormal p# 60 treatment naïve genotype 60 unresectable locally advanced 60 LibiGel ® 60 LEUKINE 60 Loceryl ® 60 Novel Oral 60 FORWARD LOOKING INFORMATION WITHIN 60 PEG SN# 60 hyperplasia BPH 60 q8h 60 Columnist Filip Bondy 60 metastatic neuroendocrine tumors 60 STOP COMPLAINING AND 60 directed radiotherapeutic antibody 60 HuMax 60 cisplatin resistant 60 colesevelam HCl 60 RON Notch 60 Dose Ranging Study 60 vitamin B# folic acid 60 topoisomerase II inhibitor 60 IIIa inhibitor 60 venous thrombosis indications 60 secretory phospholipase A2 60 thromboxane A2 60 Prospective Randomized 60 BioSante licensees 60 limiting toxicity DLT 60 Denufosol 60 asymptomatic metastatic 60 rheumatoid arthritis osteoarthritis ankylosing 60 Delta opioid receptor 60 Lymphocytic 60 Treatment Experienced 60 fluoropyrimidine 60 receiving VELCADE 60 THE OPTION MAY 60 Maurice Sendak HarperTrophy FP 60 Fludara 60 Daclizumab 60 Clinical Trial Evaluating 60 Raptiva r 60 selectively inhibited 60 Muscular colt 60 mapatumumab 60 Single Dose 60 biomimetics non 60 mg/m2 cohort 60 AIDS prophylaxis congestive 60 miconazole Lauriad R 60 Onrigin 60 sodium Injection 60 ospemifene 60 anaphylactic reactions bronchospasm 60 REGN# 60 cerebral oximeter available 60 HCl PEPCID ® famotidine 60 EBMT criteria 60 humanised monoclonal antibody 60 Improves Outcomes 60 targeted diseased tissues 60 Phase 2a Trial 60 metastatic castrate resistant 60 Taxotere ® 60 ULORIC 60 non nucleoside inhibitor 60 Phase 1a clinical 60 midstage clinical 60 FULL IMPACT 60 personalized cellular immunotherapy 60 PLX MS 60 Dextofisopam 60 PrevOnco 60 selectively inhibit replication 60 4mg/kg 60 chronic eosinophilic leukemia 60 antiangiogenic agent 60 thetreatment 60 Vectical 60 THAT ARE DIFFICULT TO 60 budesonide foam 60 assigned PDUFA 60 piperacillin tazobactam 60 Bosutinib 60 via intradermal injections 60 cancer mCRC 60 Demonstrates Efficacy 60 Silodosin 60 COU AA 60 tPA antithrombotics anticoagulation therapy 60 antibody MT# 60 corticotropin injection 60 Clolar ® 60 oral methylnaltrexone 60 Cynosure anticipates 60 Trial Issue www.emagazine.com 60 tranquilizers diazepam 60 HuMax TAC 60 ONCASPAR 60 agents Tabun Sarin 60 OvaRex R 60 hide reddened eyes 60 candesartan cilexetil 60 systemic RNAi therapeutic 60 FOLFIRI alone 60 TM Aganocide 60 nephropathic cystinosis cystinosis 60 novel topoisomerase 60 dimebon latrepirdine 60 pharmacodynamic profiles 60 sodium thiosulfate STS 60 Renal Impairment 60 elotuzumab 60 leukemia multiple myeloma 60 Cancer Incidence Mortality 60 BY WILLA J. 60 mastercard cialis pillsgeneric cialis 60 i h r 60 omega interferon 60 By BILL PLUNKETT 60 resistant hormone refractory 60 known dihydropyrimidine dehydrogenase 60 refractory indolent non 60 hypertrichosis occurred 60 evaluating intravenous picoplatin 60 esophageal candidiasis 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 Glycopyrrolate 60 inhibit oxidative stress 60 treat chronic sinusitis 60 investigational monoclonal antibody 60 oral mTOR inhibitor 60 serum urate 60 0 SHOTS OFF 60 PRIMO CABG2 60 carboplatin paclitaxel 60 Cloretazine ® 60 OR ACHIEVEMENTS IMPLIED 60 CD# expressing 60 mCRC patients 60 itraconazole Sporanox 60 By BEVERLY CORBELL 60 taxane chemotherapy administered 60 CEL SCI Phase III 60 MCyR 60 steroid refractory GvHD 60 markets HP Acthar 60 MelaFind R 60 Evidence Therapeutic 60 SUCCEED trial 60 Receives Milestone Payment 60 Kuvan sapropterin dihydrochloride 60 monoclonal antibody conjugated 60 NAVISTAR R 60 By MIKE SACCONE 60 Phase Ib IIa 60 targeted antifolate 60 benign prostatic hyperplasia enlarged 60 Resurgex Plus R 60 OMP #R# 60 Christopher McDougall Knopf 60 torezolid phosphate 60 K ras mutations 60 Sapacitabine 60 REM Scissor Sisters 60 certolizumab 60 epoetin alpha 60 rALLy trial 60 insulin glulisine 60 heavily pretreated 60 ADP receptor antagonist 60 VIVITROL ® 59 TransVax TM 59 CALGB # [001] 59 relapsed CLL 59 im peramivir 59 abacavir lamivudine 59 tumor xenograft models 59 Pemetrexed 59 Zemiva TM 59 Ph + acute lymphoblastic 59 Albuferon TM 59 vivo toxicology 59 generation purine nucleoside 59 Receives Orphan Drug 59 trastuzumab Herceptin ® 59 Pre RELAX AHF 59 orally inhaled 59 Interferon beta 59 morphometric vertebral fractures 59 damage cirrhosis liver 59 DASISION 59 registrational trial 59 visit www.targanta.com 59 Advaxis Phase 59 polyneuropathy HIV DSP 59 cervix colon 59 elderly myelodysplastic syndromes 59 lung esophageal 59 PV module efficiencies 59 Carotid Revascularization Endarterectomy vs. 59 advanced malignant hepatic 59 FDA APPROVES 59 Hepatocellular Carcinoma HCC 59 specified primary endpoint 59 deCODE ProstateCancer TM 59 hepatocellular carcinoma liver 59 EXECUTIVE SUMMARY II 59 CMV seropositive 59 NiteLites continually 59 investigational oral hepatitis C 59 myelofibrosis polycythemia vera 59 CML CP 59 website www.celsion.com 59 RoACTEMRA 59 Naive Patients 59 StromaCel Inc.